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Background: Fluralaner is a new antiparasitic drug that was recently introduced as BravectoTM chewable tablets for
the treatment of tick and flea infestations in dogs. Most marketed tick products exert their effect via topical application
and contact exposure to the parasite. In contrast, BravectoTM delivers its acaricidal activity through systemic exposure. Tick
exposure to fluralaner occurs after attachment to orally treated dogs, which induces a tick-killing effect within 12 h. The
fast onset of killing lasts over the entire treatment interval (12 weeks) and suggests that only marginal uptake by ticks is
required to induce efficacy. Three laboratory studies were conducted to quantify the extent of uptake by comparison of
ticks’ weight and coxal index obtained from BravectoTM-treated and negative-control dogs.
Methods: Three studies were conducted using experimental tick infestation with either Ixodes ricinus or Ixodes scapularis
after oral administration of fluralaner to dogs. All studies included a treated (BravectoTM chewable tablets, MSD Animal
Health) and a negative control group. Each study had a similar design for assessing vitality and weighing of ticks collected
from dogs of both groups. Additionally, in one study the coxal index (I. ricinus) was calculated as a ratio of tick’s ventral
coxal gap and dorsal width of scutum. Tick weight data and coxal indices from BravectoTM-treated and negative-control
groups were compared via statistical analysis.
Results: Ticks collected from BravectoTM-treated dogs weighed significantly less (p≤ 0.0108) than ticks collected from
negative-control dogs, and their coxal index was also significantly lower (p < 0.0001). The difference in tick weights was
demonstrated irrespective of the tick species investigated (I. ricinus, I. scapularis). At some assessments the mean tick
weights of BravectoTM-treated dogs were significantly lower than those of unfed pre-infestation (baseline) ticks.
The demonstrated tick-killing efficacy was in the range of 94.6 – 100 %.
Conclusions: Tick weights and coxal indices confirm that a minimal uptake results in a sufficient exposure of
ticks to fluralaner (BravectoTM) and consequently in a potent acaricidal effect.
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Numerous options for tick control in companion animals
are known and used by veterinarians and pet owners. Exist-
ing commercial products are usually topical treatments
such as spot-ons, sprays or collars, which have a tick-killing
and/or repellent effect (also known as ‘knock down’ effect
in pyrethroids [1]) via contact exposure of ticks to the
treated animal [1, 2], e.g. a dog. An alternative for tick
control in dogs that provides a different mechanism of
exposure is the systemic treatment of ticks and fleas
delivered through a chewable tablet (BravectoTM, MSD
Animal Health [3]; NexGardTM, Merial [4]). This op-
tion of tick control exerts its effect when ticks attach to
the host and are exposed to a drug from the isoxazoline
chemical class (e.g. fluralaner [3, 5]; afoxolaner [4]) that
was absorbed in the host’s gut and distributed through
the blood circulation. An uptake of the medicated tis-
sue fluid by the parasite results in a potent tick-killing
effect and also provides insecticidal effects against fleas
[3, 4, 6, 7].
Fluralaner (BravectoTM, MSD Animal Health) offers
veterinarians and dog owners long-lasting tick and flea
control after a single oral administration (12 weeks [3, 6–
10]), a fast onset of parasite-killing effect (ticks: 12 h [8];
fleas: 8 h, [6]), prevention of flea reproduction in the dogs’
living environment [7] and a favorable safety profile
[11–13] even in MDR1(−/−) Collies [14]. Fluralaner
also offers ease of administration, due to its high success
rate of being taken voluntarily when offered as a chewable
tablet to dogs [10].
Irrespective of their mode of action, the ultimate aim
of all tick control products is to provide prevention of
tick infestation, ideally before engorgement occurs and
tick-borne pathogens are transmitted. Two recently in-
troduced systemic products have demonstrated successful
tick control after a single oral administration to dogs for
4 weeks (NexGardTM [4]) or for 12 weeks (BravectoTM
[3]). However, pet owners may perceive the systemic
nature of a product as a drawback because ticks need
to attach to enable the product to become effective.
Fluralaner’s fast onset of action [8] provides strong evi-
dence that the uptake required for efficacy is extremely
small. The aim of the study described in this paper was
to investigate the extent of uptake by means of comparing
weight and coxal index of ticks obtained from fluralaner-
(BravectoTM) treated and control dogs. A significant reduc-
tion in these measurements between ticks from untreated
control dogs compared to fluralaner-treated dogs would
indicate a reduced contact time with the host as a result of
acaricidal treatment.
Methods
Three studies were conducted consisting of experimental
tick infestation of dogs after single oral administration offluralaner (BravectoTM, MSD Animal Health) to dogs.
Two studies were conducted with the European castor
bean tick, I. ricinus, and one study was conducted with the
American deer tick, also known as Blacklegged tick, I. sca-
pularis. All studies included a treated group (BravectoTM)
and a negative-control group (untreated). Dogs in the
BravectoTM-treated group were weighed before treatment.
The negative-control dogs remained either entirely un-
treated (Studies 1 and 2) or were only sham treated (Study
3). For inclusion in each study, dogs had to be clinically
healthy, without ectoparasitic product treatment three
months prior to study start, and were identified by micro-
chip numbers. Each of the studies had a similar design for
assessing tick vitality (i.e. ability of coordinated movement
after thermal stimulation) and weighing of ticks, for which
a calibrated analytical scale was used. The statistical ana-
lysis was performed using the software package SAS® (SAS
Institute Inc., Cary, NC, USA, release 9.2).
Studies 1 and 2
Study design
Four healthy Beagle dogs were clinically examined for
inclusion in the study and assigned to two study groups
(BravectoTM or negative-control group) of two dogs each.
Dogs were group-housed indoors within their correspond-
ing study group and fed a standard, commercially available
dry dog food. In both studies dogs had free access to drink-
ing water, and general health observations were performed
once daily.
Infestation
Laboratory-reared ticks were used for repeated infestation
of sedated dogs. Fifty unfed, adult female ticks were applied
directly onto the fur, along the back, lateral side, and head
of each dog. Approximately ten male ticks were additionally
applied to provide Ixodes females with the best conditions
for attachment and feeding to repletion. For the infestation
process, sedated dogs (0.1 ml medetomidinhydrochlorid/kg
bodyweight by intramuscular injection, e.g. Domitor®) were
kept separately in an infestation box for up to 3 h. In Study
1, tick infestations with I. ricinus were performed at 7 days
(week 1), 28 (±1) days (week 4), 56 days (week 8) and
84 days (week 12) after treatment. In Study 2, tick infesta-
tions with I. scapularis in the BravectoTM-group were per-
formed at 1 day after treatment (week 1), and dogs in the
negative-control group were infested three days later (due
to resource constraints). Further infestations were con-
ducted in both study groups at 31 days (week 4), 56 days
(week 8) and 84 days (week 12) after treatment.
Tick collection
Starting 1 day after the week 1 infestation, three female
ticks per dog were randomly collected (if less than three
ticks were present on dogs, the available number of ticks
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daily until no more ticks were found. After the infesta-
tions at week 4, week 8 and week 12, all ticks were col-
lected from dogs at once, approximately 48 h (I. ricinus)
or approximately 12 h (I. scapularis) after the respective
infestation.
Assessment
Collected female ticks were assessed for vitality (dead/
alive) and each female tick was weighed to quantify the
extent of fluralaner uptake since attachment. Thereafter,
ticks were photographed to further illustrate tick devel-
opment on treated versus untreated dogs. Additionally,
separate sets of 20 unfed female ticks per species (I. ricinus,
I. scapularis) were obtained from the same batch used for
the infestations during the study (i.e. these adult ticks
had not been used for host infestations). These ticks were
weighed for comparison, and henceforth are referred to as
baseline ticks.
Statistical analysis
All group comparisons were independent, testing for sig-
nificant differences in tick weights. The statistical test
applied was a two-sided, two-sample t-test. Depending
on the results of a preceding equality of variance test, ei-
ther pooled variances (equal variance situation) or the
Satterthwaite approximation (unequal variance situation)
were used for the t-test. The level of significance was set
to α = 0.05.
In both studies, comparisons of tick weights from
BravectoTM-treated and negative- control groups were
carried out for all assessment times, and additionally,
comparisons of ticks collected from BravectoTM-group
and baseline ticks were carried out.
Study 3
Study design
Ten healthy Beagle dogs (five males and five females)
were used in the study. During a pre-treatment period, a
tick infestation (I. ricinus) was conducted to evaluate the
susceptibility of each dog to experimental infestation and
for random allocation of the dogs to the study groups
based on total counts of live ticks obtained two days after
the infestation. Nine dogs with the highest tick counts
were randomized to two study groups (BravectoTM-group
of six dogs; negative-control group of three dogs). In
addition, veterinary examinations, general health observa-
tions, and the weighing of all animals were performed
during the pre-treatment period.
Infestation
Ticks of a laboratory-reared I. ricinus isolate, which was
regularly substituted with ticks caught from the field,
were used for the infestations of sedated dogs (0.1 mlmedetomidinhydrochlorid/kg bodyweight intramuscular,
e.g. Domitor®). Dogs were infested with approximately 50
viable, adult, unfed female I. ricinus ticks. Approximately
five male ticks were additionally applied to provide the
Ixodes females with the best conditions for attachment
and feeding to repletion. Infestations took place two days
before treatment to assess immediate efficacy, and 28 days
(4 weeks), 56 days (8 weeks) and 84 days (12 weeks) after
treatment to assess persistent efficacy. For the infestation
process and for sedation, dogs were kept separately in
an infestation box for up to three hours, and were then
housed individually until removal of ticks.
Tick collection
Tick removal/counts on each animal were carried out 48
(±2) hours after treatment to assess immediate efficacy,
and 48 (±2) hours following each infestation at 4, 8 and
12 weeks to assess persistent efficacy.
Assessment
The study personnel who carried out tick assessments
(i.e. vitality, weight and coxal index) were masked with
regard to the treatment status of each dog. Live and
dead ticks were counted and the intact ticks of both
groups were weighed on each assessment day. Addition-
ally, the scutal width across the dorsal side of the ticks
and the gap between the bases of the fourth pair of legs
across the ventral abdomen of the ticks were measured
using a stereomicroscope (magnification of 25). The coxal
index was then calculated as a ratio of coxal gap to scutal
width [15, 16].
Furthermore, a separate set of 20 unfed female ticks
was obtained from the same batch used for the respective
infestation at each assessment time (i.e. adult ticks had not
been infested to a dog). These ticks were also weighed for
comparison and used as baseline ticks.
Statistical analysis
The statistical analysis of tick weight and coxal index
was conducted as described in Studies 1 and 2. Adequacy
of infestation was assessed on each tick count day by de-
termining the mean tick attachment rate of live ticks in
the control group. Efficacy for the fluralaner group was
calculated at each assessment time point using geometric
(or arithmetic) means with Abbott’s formula:
Efficacy (%) = 100 x (MC – MT)/MC, where MC was
the mean number of total live attached ticks on the un-
treated dogs, and MT was the mean of total live attached
ticks on the BravectoTM-treated dogs. Log-transformed
tick counts in both study groups were compared using a
two –sample t-test. The two-sided level of significance
was set to α = 0.05. Efficacy was claimed if the efficacy
against ticks in the BravectoTM-treated group was greater
than or equal to 90 %.
Table 1 Tick weights of I. ricinus collected from BravectoTM-treated and untreated dogs in Study 1
Infestation Collection Tick weighta [mg]
BravectoTM Negative control
Mean Min Max Mean Min Max
Week 1 Daily after infestation 1.0e 0.7 1.9 2.2 1.8 3.0
1.4e 0.7 2.5 4.2 3.6 5.2
0.7e 0.5 1.3 8.4 6.2 10.2
0.6eb 0.5 0.7 21.4 19.9 23.8
0.4ec 0.3 0.6 33.2 24.9 39.1
N/A N/A N/A 211.5 133.7 290.8
N/A N/A N/A 186.9 22.4 402.4
N/A N/A N/A 227.0d 179.9 300.8
Week 4 2 days after infestation 0.8e 0.4 2.3 3.9 2.8 6.1
Week 8 1.5e 0.7 3.0 4.1 2.0 8.4
Week 12 1.5e 0.5 2.8 4.3 3.1 9.4
N/A Not applicable because no ticks were found on dogs
aArithmetic mean, minimum (Min) and maximum (Max) tick weight
b, c, dLess than three ticks per dog were present at tick collection. Therefore, the mean tick weight was derived from five (b) or three ticks (c) in the treated group,
and from three ticks (d) in the negative-control group
eTick weight in treated group is significantly different from negative control (p ≤ 0.0006)
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All dogs (treated and control) were healthy at study enroll-
ment, on day of treatment administration and throughout
the duration of each study. At treatment all dogs swallowed
the tablet and therefore were successfully dosed, and
no adverse events were observed in any treated dog.Table 2 Tick weights of I. scapularis collected from BravectoTM-treat
Infestation Collection Tick weighta [m
BravectoTM
Mean










Week 4 Approx.12 h after infestation 1.7
Week 8 1.6e
Week 12 1.6e
N/A Not applicable because no ticks were found on dogs
aArithmetic mean, minimum (Min) and maximum (Max) tick weight
b, cLess than three ticks per dog were present at tick collection. Therefore, the mea
cNo statistical analysis was performed because only one tick was recovered from tre
dThe mean tick weight was derived from seven ticks in the negative-control group
and was included in the assessment
eTick weight in treated group is significantly different from negative control (p-valuIn all studies, the mean attachment rates on negative
control dogs were at least 31 % at all times of assessment
demonstrating that ticks used were vigorous.
The mean tick weights of Study 1 and Study 2 are
presented in Table 1 (I. ricinus) and Table 2 (I. scapu-
laris), respectively. Photos of ticks collected daily fromed and untreated dogs in Study 2
g]
Negative control
Min Max Mean Min Max
0.7 1.2 1.7 1.5 2.4
0.6 1.9 3.6 3.1 4.1
0.6 0.8 6.2 4.8 9.4
0.4 0.9 12.2 5.9 23.5
0.4 0.8 22.8 11.4 37.5
0.6 0.6 17.8 10.1 38.7
N/A N/A 16.2 7.8 23.2
N/A N/A 23.1d 13.6 56.9d
N/A N/A 23.3 12.1 35.2
N/A N/A 21.1 11.7 30.7
1.0 2.7 1.8 1.0 2.4
1.0 2.1 1.8 1.3 2.1
0.7 2.2 1.8 1.4 2.1
n tick weight was derived from four (b) or one tick (c) in the treated group
ated group
because a fourth tick (d) dropped from one control dog after tick collection
es in the range of 0.0108 to < 0.0001)
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sented in Fig. 1 (I. ricinus) and Fig. 2 (I. scapularis).
For Study 3 (I. ricinus) the mean tick weight results are
presented in Table 3, the coxal indices in Table 4 and tick
efficacy results are given in Table 5.
Study 1: Oral treatment of fluralaner (BravectoTM) against
experimental infestation of I. ricinus on dogs
All ticks collected from BravectoTM-treated dogs after
infestation at week 1, week 4, week 8 and week 12 were
dead, and all ticks collected from negative-control dogs
were alive.
Tick weights
Baseline ticks weighed in the range of 1.3 to 2.1 mg,
with a mean tick weight of 1.7 mg.
At all assessment times, the mean weights of ticks col-
lected from BravectoTM-treated dogs were significantly
lower than the mean weights of ticks collected fromFig. 1 Example of I. ricinus - tick growth on an untreated dog (left) in com
(right) (Study 1)negative-control dogs (p-values in the range of p = 0.0006
to p < 0.0001). The mean weights of ticks collected from
BravectoTM-treated dogs in week 1 and from week 4 to
week 12 were significantly lower than those of baseline
ticks (in both cases p < 0.0001).
Study 2: Oral treatment of fluralaner (BravectoTM) against
experimental infestation of I. scapularis on dogs
All ticks collected from BravectoTM-treated dogs were dead,
and all ticks collected from negative-control dogs were
alive.
Tick weights
Baseline ticks weighed in the range of 1.3 – 2.1 mg, with
a mean tick weight of 1.7 mg.
At all assessment times, the mean weights of ticks col-
lected from BravectoTM-treated dogs were lower than the
mean weights of ticks collected from negative-control dogs,
and at all assessment times except at the 4-week assessmentparison to ticks killed after infesting a dog treated with BravectoTM
Fig. 2 Example of I. scapularis - tick growth on an untreated dog (left) in comparison to ticks killed after infesting a dog treated with BravectoTM
(right) (Study 2)
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was significant (p ≤ 0.0108). The mean weights of ticks from
BravectoTM-treated dogs at daily collections after the week
1 infestation were also significantly lower than those of
baseline ticks (p < 0.0001).
Study 3: Oral treatment of fluralaner (BravectoTM) against
experimental infestation of I. ricinus on dogs
At all infestation time points (including first infestation
when the dogs’ ability to retain ticks was assessed), allcontrol dogs were adequately infested (infestation rate of
at least 25 % of the number of applied ticks), and there-
fore the efficacy calculation is considered valid.
Efficacy
Based on geometric (and arithmetic) means, the immediate
efficacy against an existing tick infestation after BravectoTM
treatment was 100 % (100 %), and persistent efficacy against
tick challenges at 4, 8 and 12 weeks following BravectoTM
treatment was 100 % (100 %), 99.5 % (99.1 %) and 94.6 %
Table 3 Tick weights of I. ricinus collected from BravectoTM-
treated and untreated dogs in Study 3
Infestation Collection Tick weight [mg]
BravectoTM Negative control
Meana Stdevb Meana Stdevb
Week 1 2 days after infestation 4.32c 3.51 10.88 5.85
Week 4 1.41c 1.31 3.80 0.59
Week 8 2.26c 1.82 3.65 0.72
Week 12 2.38c 1.72 3.76 0.59
aArithmetic mean
bStandard deviation
cTick weight in treated group is significantly different from negative
control (p < 0.0001)
Table 5 Mean tick counts and tick-killing efficacy after BravectoTM
treatment conducted in Study 3
Assessment timea Mean tick countsb [n] (control/treated) Efficacy [%]
(I. ricinus)
Week 1 34.2/0c (34.3/0) 100 (100)
Week 4 40.9/0c (41.0/0) 100 (100)
Week 8 38.6/0.2c (38.7/0.3) 99.5 (99.1)
Week 12 38.5/2.1c (38.7/2.2) 94.6 (94.4)
aEfficacy assessment either 48 (±2) hours after treatment (week 1) or 48 (±2)
hours after re-infestation (week 4, 8 and 12)
bGeometric mean results; in parenthesis () the arithmetic mean results
are given
cLog-transformed live tick count in the treated group is significantly different
from negative control (p < 0.0001)
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transformed live-attached tick counts in the treated
group differed significantly from the log-transformed
live-attached tick counts in the negative-control group
(p ≤ 0.0001).
Tick weights
Baseline ticks had a mean tick weight of 1.99 ± 0.23 mg.
At all assessment times, the mean weights of ticks col-
lected from BravectoTM-treated dogs were significantly
lower than the mean weights of ticks collected from the
negative-control dogs (p < 0.0001). The mean weight of
ticks collected from BravectoTM-treated dogs after the
4-week infestation was also significantly lower than that
of baseline ticks (p < 0.0144).
Coxal index
At all assessment times, the mean coxal indices of ticks
collected from BravectoTM-treated dogs were significantly
lower than the mean coxal indices of ticks collected from
negative-control dogs (p < 0.0001).
Discussion
All studies demonstrated a consistent and high acaricidal
efficacy and favorable tolerability after administration ofTable 4 Coxal indices of I. ricinus collected from BravectoTM-
treated and untreated dogs in Study 3
Infestation Collection Coxal index
BravectoTM Negative control
Meana Stdevb Meana Stdevb
Week 1 2 days after infestation 0.80c 0.26 1.14 0.20
Week 4 0.49c 0.21 0.74 0.07
Week 8 0.58c 0.26 0.68 0.06
Week 12 0.59c 0.25 0.73 0.07
aArithmetic mean
bStandard deviation
cCoxal index in the treated group is significantly different from negative
control (p < 0.0001)BravectoTM to dogs. Twelve weeks of efficacy against ticks
of Ixodes spp. was demonstrated in accordance with
BravectoTM chewable tablets’ label claims [3], irrespective
of the tick species tested (I. ricinus, I. scapularis). Even
short-term tick exposure of approximately 12 h to Bravec-
toTM-treated dogs resulted in a potent tick-killing effect (I.
scapularis), a finding that supports the 12-h speed of kill
claim for ticks [3, 8].
To enable tick weight comparisons and allow for stat-
istical analysis with sufficient numbers of ticks in treated
and untreated groups, dogs in all studies were kept under
controlled laboratory conditions which included avoidance
of any potential influence that could cause ticks to detach
during the infestation periods. In contrast to the home en-
vironment wherein dogs are often encouraged to be active
(e.g. at dog walks, play time) and routinely experience in-
tense human-dog and dog-dog interactions, the controlled
study conditions restricted the handling of dogs to a mini-
mum during the times when ticks were present. It can be
assumed that this reduced the number of detaching ticks
(particularly of dead ticks on treated dogs) and thereby en-
abled a statistical analysis of tick weights in both groups.
In line with the high consistency of acaricidal effect
(i.e. tick efficacy) observed in the studies, the tick weight
evaluations also demonstrated highly consistent results.
The mean weights of ticks that were all killed when col-
lected from BravectoTM-treated dogs were lower than the
mean weights of ticks from negative-control dogs, statis-
tical comparison shows a significant difference at all as-
sessment times except at week 4 (Study 2). The significant
difference was demonstrated over the entire duration of
tick efficacy (i.e. over 12 weeks, p ≤ 0.0108) and for both
Ixodes species tested. Thus, the tick weight results of all
three studies provide strong evidence that ticks encounter-
ing BravectoTM-treated dogs are killed very quickly after
attachment, and that the uptake of fluralaner before ticks
start dying is minimal. This conclusion is substantiated by
the coxal indices (Study 3), which were significantly lower
in BravectoTM-treated dogs compared to negative controls
consistently over a 12 week period (p < 0.0001).
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killing effect [8] and suggest that BravectoTM is able to
reduce the risk of tick-borne disease transmission in
treated dogs. A recent transmission study further sup-
ports the conclusion and demonstrates a 100 % pre-
ventive effect over a 12-week period against Babesia
canis transmission using infected Dermacentor reticu-
latus for repeated infestations of fluralaner (Bravec-
toTM) -treated dogs in comparison to negative control
dogs [17].
The baseline ticks in the first two studies had mean
tick weights of 1.7 mg (I. ricinus, I. scapularis) whereas
in a third study the mean tick weight of baseline-I. rici-
nus was slightly higher (2.0 mg). Surprisingly, on some
occasions the mean weights of ticks obtained from
BravectoTM-treated dogs were significantly lower than
those of baseline ticks, which had not been infested to
dogs (p ≤ 0.0162). This can be explained with a drying of
ticks after being killed on treated dogs. The data support
the very low uptake by ticks following systemic treatment
of dogs that is further illustrated by the tick photographs
in Figs. 1 and 2.Conclusions
Systemic treatment using oral administration of flurala-
ner (BravectoTM) effectively controls tick infestations on
dogs. The tick weights and coxal indices determined in
these studies confirm that a minimal uptake results in
sufficient exposure to fluralaner to induce a potent acari-
cidal effect in treated dogs.Compliance statement
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